Cerebrospinal Fluid Amyloid-beta Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study: A Pilot Study

Nicolaas A. Verwey*, Charlotte E. Teunissen, Jeroen J.M. Hoozemans, Annemieke J.M. Rozemuller, Philip Scheltens, Yolande A.L. Pijnenburg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

To investigate amyloid-β (Aβ) in frontotemporal dementia (FTD), cerebrospinal fluid (CSF) Aβ38, Aβ40, and Aβ42 in frontotemporal lobar degeneration (FTLD; N = 18 genetically and/or pathologically confirmed and N = 8 FTD with concomitant amyotrophic lateral sclerosis) were compared with Alzheimer's disease (AD; pathological or Pittsburgh-compound-B Positron-emission-tomography (PIB-PET) positive; N = 25) and controls (N = 24). For all the Aβ subtypes, group difference was seen and post-hoc analysis revealed lower levels in FTLD compared to controls (p≤0.05). Aβ42/40 ratio showed no difference between FTLD and controls; however, a difference was seen between AD versus FTLD (p < 0.01). This is an intriguing finding, suggesting a possible role of Aβ in FTLD pathogenesis.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalJournal of Alzheimer's Disease
Volume71
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • Alzheimer's disease
  • amyloid
  • frontotemporal dementia
  • frontotemporal lobar degeneration

Fingerprint

Dive into the research topics of 'Cerebrospinal Fluid Amyloid-beta Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study: A Pilot Study'. Together they form a unique fingerprint.

Cite this